Roche’s Avastin Fails to Win NICE Backing for Ovarian Use

Roche Holding AG’s anti-tumor drug Avastin failed for the second time in two months to win the backing of the U.K.’s health-cost regulator as a treatment for ovarian cancer in a draft decision issued today.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.